PMGC (ELAB) Competitors $5.70 -0.07 (-1.21%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$5.73 +0.03 (+0.46%) As of 09/16/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ELAB vs. VYNE, PMCB, SNOA, GNPX, NLSP, AIM, CDIO, ALZN, ACXP, and APLMShould you be buying PMGC stock or one of its competitors? The main competitors of PMGC include VYNE Therapeutics (VYNE), Nuvilex (PMCB), Sonoma Pharmaceuticals (SNOA), GENPREX (GNPX), NLS Pharmaceutics (NLSP), AIM ImmunoTech (AIM), Cardio Diagnostics (CDIO), Alzamend Neuro (ALZN), Acurx Pharmaceuticals (ACXP), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. PMGC vs. Its Competitors VYNE Therapeutics Nuvilex Sonoma Pharmaceuticals GENPREX NLS Pharmaceutics AIM ImmunoTech Cardio Diagnostics Alzamend Neuro Acurx Pharmaceuticals Apollomics PMGC (NASDAQ:ELAB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Do analysts prefer ELAB or VYNE? VYNE Therapeutics has a consensus price target of $6.25, indicating a potential upside of 1,942.48%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than PMGC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VYNE Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ELAB or VYNE more profitable? PMGC has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -8,097.69%. PMGC's return on equity of -62.73% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PMGCN/A -62.73% -52.83% VYNE Therapeutics -8,097.69%-77.57%-63.09% Which has better valuation & earnings, ELAB or VYNE? PMGC has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMGC$1.71M1.40-$6.25M-$433.87-0.01VYNE Therapeutics$500K15.59-$39.83M-$0.90-0.34 Which has more risk and volatility, ELAB or VYNE? PMGC has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Does the media refer more to ELAB or VYNE? In the previous week, VYNE Therapeutics had 1 more articles in the media than PMGC. MarketBeat recorded 3 mentions for VYNE Therapeutics and 2 mentions for PMGC. PMGC's average media sentiment score of 1.45 beat VYNE Therapeutics' score of 0.96 indicating that PMGC is being referred to more favorably in the media. Company Overall Sentiment PMGC Positive VYNE Therapeutics Positive Do insiders & institutionals believe in ELAB or VYNE? 22.2% of PMGC shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 0.2% of PMGC shares are owned by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryVYNE Therapeutics beats PMGC on 8 of the 15 factors compared between the two stocks. Get PMGC News Delivered to You Automatically Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELAB vs. The Competition Export to ExcelMetricPMGCDIVERSIFIED OPS IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$2.45M$16.49B$15.10B$10.31BDividend YieldN/A3.96%3.76%4.63%P/E Ratio-0.0112.5110.3626.51Price / Sales1.408.667.16123.58Price / CashN/A48.2144.9560.46Price / Book0.142.722.386.29Net Income-$6.25M$952.28M$922.91M$270.51M7 Day Performance27.80%2.46%1.95%1.95%1 Month Performance-15.62%18.68%15.48%6.33%1 Year Performance-99.63%14.39%11.34%25.62% PMGC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELABPMGC0.8411 of 5 stars$5.70-1.2%N/A-99.6%$2.45M$1.71M-0.0118Positive NewsVYNEVYNE Therapeutics2.7638 of 5 stars$0.29-1.6%$6.25+2,077.7%-83.7%$7.31M$500K-0.3230Short Interest ↓PMCBNuvilex0.8108 of 5 stars$1.07-5.6%N/A-47.1%$7.26MN/A0.414Earnings ReportGap DownHigh Trading VolumeSNOASonoma Pharmaceuticals0.6535 of 5 stars$4.36-4.6%N/A-0.2%$7.15M$14.29M-1.77180Positive NewsGap DownGNPXGENPREX1.2035 of 5 stars$0.21+1.6%N/A-30.5%$6.99MN/A0.0020News CoverageShort Interest ↑Gap DownNLSPNLS PharmaceuticsN/A$1.94-2.0%N/A+1,458.8%$6.98MN/A0.006AIMAIM ImmunoTech1.7932 of 5 stars$2.57-0.8%$275.00+10,600.4%-91.6%$6.96M$121K-5.4720Gap DownCDIOCardio Diagnostics1.4568 of 5 stars$3.95+8.8%N/A-52.2%$6.95M$40K0.001ALZNAlzamend Neuro3.5403 of 5 stars$2.37+0.4%$45.00+1,798.7%-84.0%$6.87MN/A0.004Gap DownACXPAcurx Pharmaceuticals2.2168 of 5 stars$4.19+1.5%$31.00+639.9%-89.7%$6.62MN/A-0.393APLMApollomics0.6332 of 5 stars$5.89+8.4%N/A-9.7%$6.49MN/A0.0045Positive NewsGap Down Related Companies and Tools Related Companies VYNE Alternatives PMCB Alternatives SNOA Alternatives GNPX Alternatives NLSP Alternatives AIM Alternatives CDIO Alternatives ALZN Alternatives ACXP Alternatives APLM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELAB) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMGC Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMGC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELAB Stock Alerts